New drug cocktail aims to wipe out hidden colorectal cancer cells

NCT ID NCT07071961

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests two drugs, regorafenib and lorigerlimab, in people with high-risk colorectal cancer who have no visible tumors but still have cancer DNA in their blood after standard treatment. The goal is to see if the combination can clear these hidden cancer cells and improve outcomes. Only 16 participants are enrolled, and the study is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: regorafenib and lorigerlimab
What this could lead to: If successful, this combination could help eliminate remaining cancer cells in high-risk colorectal cancer patients, potentially preventing recurrence.
What could go wrong: This is a small, early-phase trial (16 participants) that is currently suspended. The drugs may cause significant side effects, and the approach may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER HIGH RISK PATIENTS REGORAFENIB

Contacts and locations

Locations

MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.